| |||||||||

Revenue by Geography (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
|
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
||
| Revenue - International | 0 | 0 | 0 | 0 | 3.37B | |||
| Revenue - US | 0 | 0 | 0 | 0 | 10.0B | |||
| Total Revenue | 4.62B | 6.63B | 9.28B | 11.7B | 13.4B | |||
Revenue by Segment (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
|
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
||
| Revenue - Licensing | 0 | 0 | 0 | 2.11B | 0 | |||
| Revenue - Product Sales | 0 | 0 | 0 | 9.61B | 0 | |||
| Revenue - Lucentis | 0 | 0 | 0 | 0 | 875M | |||
| Revenue - AVASTIN | 0 | 0 | 0 | 0 | 2.69B | |||
| Revenue - RITUXAN | 0 | 0 | 0 | 0 | 2.59B | |||
| Revenue - HERCEPTIN | 0 | 0 | 0 | 0 | 1.38B | |||
| Revenue - XOLAIR | 0 | 0 | 0 | 0 | 517M | |||
| Revenue - TARCEVA | 0 | 0 | 0 | 0 | 457M | |||
| Revenue - Nutropin products | 0 | 0 | 0 | 0 | 358M | |||
| Revenue - Thrombolytics | 0 | 0 | 0 | 0 | 275M | |||
| Revenue - Pulmozyme | 0 | 0 | 0 | 0 | 257M | |||
| Revenue - Raptiva | 0 | 0 | 0 | 0 | 108M | |||
| Total Revenue | 4.62B | 6.63B | 9.28B | 11.7B | 13.4B | |||
| ||||||